ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KOD / news
IMVT (37) CGON (42) SRRK (41) CRSP (35) ⌘ Pro Terminal →

Why KOD Stock slipped -1.57% Today — RQD Quant Desk Flash

$97.63 -1.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $97.17

Kodiak Sciences Inc (KOD) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $6.14B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KOD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KOD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kodiak Sciences Inc (NASDAQ: KOD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $97.63 (-1.57% 1D, market cap $6.14B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, KOD ranks #211 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KOD compare to IMVT and CGON in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KOD carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMVT (Immunovant Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $5.87B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, KOD leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KOD?
▼

Per KOD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468748), Kodiak Sciences Inc generated $656.3M in revenue (+25.4% YoY), -$230.0M in net income, and -$136.5M in free cash flow against $351.5M in total assets and $87.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $97.17 (-0.47%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk C-
Cash (8)Whales (17)SEC (14)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
$113 Bull$96 Base$75 Bear
📬 FREE KOD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KOD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY KOD SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)

Altman Z-Score 16.70 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$88.12-2.7% Next Q
Q2 (-2Q)
49
Grade D$85.78+17% Next Q
Q3 (-1Q)
51
Grade C-$100.40-2.8% Next Q
Current
54
Grade D+$97.63-0.7% Hist 90D α
Trajectory: D (46) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KOD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KOD currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($68.59) and Max Pain ($102.51) forces dealer call-delta covering toward $113.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KOD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KOD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why KOD Stock slipped -1.57% Today — RQD Quant Desk Flash

Kodiak Sciences Inc (KOD) slipped -1.57% to $97.63, trading at 93% of its 52-week range ($15.83 – $104). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 93% of its 52-week range ($15.83 – $104) with RSI-14 at 63 (BULLISH MOMENTUM).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $97.63 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D+ (Sell) backed by 0% gross margin and $0 annual free cash flow.
Live KOD Headlines & Catalysts
MARKET WIREBenzinga • 6d ago
10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KOD)

  • ✓Walkthrough of KOD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KOD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +128.86%▲ ASCENDING TRIANGLE
2026-11-04O $99.18H $99.18L $97.63C $97.63VOL 595.7K
SUP: $30.05SMA50: $68.59SMA200: $43.54
$109.7$85.98$62.23$38.48$14.73SUP $30.05$97.632026-05-052026-06-222026-08-062026-09-222026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KOD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KOD Butterfly Map → + Track KOD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
27.0%/yr Implied 5Y Growth

vs. +25.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KOD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KOD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KOD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KOD)

Health Care Rank #211 of 1015 ⚔️ IMVT vs KOD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KOD vs. IMVT, CGON, SRRK, CRSP)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kodiak Sciences Inc (KOD) ranks #211 by composite RQD confidence (54/100, grade D+) and #141 by equity capitalization ($6.14B). Within this direct 5-issuer industry benchmark cohort, KOD leads on earnings valuation at N/A trailing P/E, while CGON leads on capital efficiency and profitability with -20.8% ROIC and — gross margin. KOD currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KOD ACTIVE
Kodiak Sciences Inc
D+ 54/100 — — -35.0% -1.57% $6.14B Benchmark Subject
IMVT
Immunovant Inc.
D- 37/100 — — -35.0% -2.60% $5.87B /imvt-vs-kod →
CGON
CG Oncology Inc.
D- 42/100 — — -20.8% -4.20% $5.49B /cgon-vs-kod →
SRRK
Scholar Rock Holding Corporation
D- 41/100 — — -35.0% -2.25% $5.23B /srrk-vs-kod →
CRSP
CRISPR Therapeutics AG
D- 35/100 — — -30.6% -2.78% $4.83B /crsp-vs-kod →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001468748 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kodiak Sciences Inc (KOD) reported GAAP revenue of $656.3M (+25.4% vs. FY2024 revenue of $523.2M , and -15.5% cumulative change since FY2023) , GAAP net income of -$230.0M, operating cash flow of -$136.0M, and free cash flow of -$136.5M (-16.0% YoY). On the balance sheet, KOD closed FY2025 with $351.5M in total assets against $87.4M in total debt (Altman Z-Score: 16.70, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $656.3M -$230.0M -$136.0M -$136.5M $351.5M $87.4M
FY2024 (FY) 2024-12-31 $523.2M -$176.2M -$117.3M -$117.7M $335.6M $83.4M
FY2023 (FY) 2023-12-31 $776.5M -$260.5M -$154.2M -$154.2M $3.47B $812.1M

3. KOD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KOD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kodiak Sciences Inc (NASDAQ: KOD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $97.63 (-1.57% 1D, market cap $6.14B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, KOD ranks #211 in composite RQD confidence.

How does KOD compare to IMVT and CGON in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KOD carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMVT (Immunovant Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $5.87B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, KOD leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KOD?

Per KOD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468748), Kodiak Sciences Inc generated $656.3M in revenue (+25.4% YoY), -$230.0M in net income, and -$136.5M in free cash flow against $351.5M in total assets and $87.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KOD trading relative to its 50-day, 200-day, and 52-week technical levels?

KOD last traded at $97.63 (-1.57% on volume of 595,652 shares), positioning the stock +42.34% above its 50-day simple moving average ($68.59) and +124.23% above its 200-day simple moving average ($43.54). Across its 52-week range of $15.83 to $104.00, KOD sits at the 92.8% percentile with a 14-day RSI of 63.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($85.43 to $109.83).

Direct Sub-Reports: KOD RQD Cockpit KOD 12M Forecast KOD Earnings & Move KOD Dividends & DRIP KOD Insiders & 13F KOD Whale Options KOD Profit Sankey KOD News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

KOD — Kodiak Sciences Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kodiak Sciences Inc (KOD) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $97.63 (-1.57% 1D, market capitalization $6.14B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -13.3%, and free cash flow yield of -2.16%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 0.90x equity beta, Altman Z-Score of 16.70, Piotroski F-Score of 4/9, and Debt/Equity of 0.52x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kodiak Sciences Inc is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The issuer has a market capitalization of $6.3B. The reported revenue of — across all three periods indicates no recognized revenue in the source financials.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kodiak Sciences Inc (KOD) reported $656.3M in annual revenue (up from $523.2M in FY2024, +25.4% YoY) and -$230.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($776.5M revenue, -$260.5M net income) through FY2025, KOD scaled operating cash flow to -$136.0M and free cash flow to -$136.5M, backed by $351.5M in total assets against $87.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 54/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -2.16% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $15.83 – $104.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -13.3% operating margins and a 0.90x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. Upstream suppliers, downstream customers, and sector correlations are therefore — The clinical-trial readout flagged on the news wire is the primary 2nd-order item to monitor, since outcomes in the company's pipeline would affect the balance-sheet trajectory given that the company currently reports no revenue and negative free cash flow in every period shown.

  • Key Question #1: Can KOD sustain or expand its -13.3% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $656.3M and free cash flow of -$136.5M, how will capital allocation balance growth reinvestment against $87.4M in total debt?
  • Key Question #3: How sensitive is KOD's 35.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.90x)?

KOD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kodiak Sciences Inc (KOD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KOD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KOD Bull vs. Bear Conversation Board — What's Your Call at $97.63?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KOD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KOD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $119.02 (+20.0%)
📌 Pinned Debate

Institutional positioning scores 18 of 20 on the Whale 13F Flow pillar, the strongest pillar in the RQD rating, and cash grew to $209.9

Long KOD at $99.18 targeting $119.02. Institutional positioning scores 18 of 20 on the Whale 13F Flow pillar, the strongest pillar in the RQD rating, and cash grew to $209.9M in FY 2025.. Institutional whale score is 17/20 and the risk/reward vs. the $18.05 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — KOD's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $80.34 (-19.0%)
Spot @ $99.18

ROIC of -35%, FCF yield of -2.16%, and zero reported revenue across all three periods leave the fundamental cash engine scoring 8 of 20

Sitting on the sidelines or leaning short KOD above $99.18. ROIC of -35%, FCF yield of -2.16%, and zero reported revenue across all three periods leave the fundamental cash engine scoring 8 of 20.. Until Fundamental Cash Engine (8/20) and FCF yield (-2.16%) inflect higher, upside is capped near $104.00.

LIVE TAPE